MedTrace Logo

Evaluation of DiaSorin LIAISON® PTX3 (Long Pentraxin 3) Assay in Patients With Pneumonia

NCT06491004 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 281

Last updated 2024-07-08

No results posted yet for this study

Summary

LIAISON® PTX3 is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of Long Pentraxin 3 (PTX3) in human plasma samples.

LIAISON® PTX3, in conjunction with clinical evaluation and other laboratory findings, may serve as an aid in the determination of disease severity and prognosis of patients with community-acquired (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).

Conditions

Interventions

DIAGNOSTIC_TEST

PTX3 assay

PTX3 dosage by the in vitro medical device in evaluation.

Sponsors & Collaborators

  • Diasorin Italia S.p.A.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2024-03-29
Completion
2024-03-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06491004 on ClinicalTrials.gov